[Hemodynamic and humoral changes following intravenous administration of xamoterol in patients with heart failure and coronary heart disease]. 1990

H H Erlemeier, and W Kupper, and W Bleifeld
Abteilung Kardiologie, Universitätskrankenhaus Eppendorf, Hamburg.

Xamoterol is a beta-1 selective partial adrenoceptor agonist. Thirty patients (one female, 29 male, mean age 56 +/- 8 years) with coronary artery disease and mild to moderate heart failure, according to NYHA classes II and III, were studied before and 15 min after intravenous administration of 0.2 mg/kg xamoterol, at rest and during standard, supine bicycle exercise. At rest, the pulmonary capillary wedge pressure fell by 39% (p = 0.0001) and the cardiac index increased by 7% (p = 0.0084); heart rate increased only slightly. With exercise, cardiac index did not change and the pulmonary capillary wedge pressure decreased by 11% (p = 0.0003). In addition, the heart rate dropped from 115 to 105 bt/min (p = 0.0001) which resulted in a decrease of the rate pressure product by 9% (p = 0.0041). Arterial blood pressure remained unchanged. Norepinephrine plasma levels did not change at rest or during exercise, whereas at rest plasma renin activity dropped by 18% (p less than 0.05) and by 20% (p less than 0.05) during exercise. No untoward side effects were observed and the drug was well tolerated. In conclusion, xamoterol, given acutely to patients with heart failure NYHA classes II or III exerted advantageous hemodynamic effects at rest and during exercise.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005260 Female Females

Related Publications

H H Erlemeier, and W Kupper, and W Bleifeld
January 1988, European journal of clinical pharmacology,
H H Erlemeier, and W Kupper, and W Bleifeld
June 1989, Cardiologia (Rome, Italy),
H H Erlemeier, and W Kupper, and W Bleifeld
January 1979, Transactions of the Association of American Physicians,
H H Erlemeier, and W Kupper, and W Bleifeld
January 2023, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
H H Erlemeier, and W Kupper, and W Bleifeld
May 1988, Lancet (London, England),
H H Erlemeier, and W Kupper, and W Bleifeld
July 1990, Lancet (London, England),
H H Erlemeier, and W Kupper, and W Bleifeld
November 1983, The American journal of cardiology,
Copied contents to your clipboard!